Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1962 2
1964 3
1966 1
1967 3
1968 3
1969 1
1970 2
1971 1
1972 2
1974 2
1975 2
1976 4
1977 5
1978 7
1979 7
1980 7
1981 9
1982 9
1983 15
1984 8
1985 16
1986 17
1987 20
1988 14
1989 19
1990 18
1991 15
1992 19
1993 10
1994 28
1995 22
1996 31
1997 36
1998 44
1999 49
2000 54
2001 47
2002 42
2003 56
2004 48
2005 69
2006 41
2007 49
2008 54
2009 37
2010 47
2011 53
2012 52
2013 52
2014 31
2015 37
2016 33
2017 39
2018 36
2019 31
2020 27
2021 36
2022 26
2023 11

Text availability

Article attribute

Article type

Publication date

Search Results

1,377 results

Results by year

Filters applied: . Clear all
Page 1
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.
Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim YS, Yoshida J, Gabryelski L, Pedley A, Eves K, Tipping R, Guris D, Kartsonis N, Dorr MB; MODIFY I and MODIFY II Investigators. Wilcox MH, et al. Among authors: yoshida j. N Engl J Med. 2017 Jan 26;376(4):305-317. doi: 10.1056/NEJMoa1602615. N Engl J Med. 2017. PMID: 28121498 Free article. Clinical Trial.
A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19.
Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, Mutoh Y, Homma Y, Terada M, Ogawa T, Kashizaki F, Yokoyama T, Koba H, Kasahara H, Yokota K, Kato H, Yoshida J, Kita T, Kato Y, Kamio T, Kodama N, Uchida Y, Ikeda N, Shinoda M, Nakagawa A, Nakatsumi H, Horiguchi T, Iwata M, Matsuyama A, Banno S, Koseki T, Teramachi M, Miyata M, Tajima S, Maeki T, Nakayama E, Taniguchi S, Lim CK, Saijo M, Imai T, Yoshida H, Kabata D, Shintani A, Yuzawa Y, Kondo M. Doi Y, et al. Among authors: yoshida j. Antimicrob Agents Chemother. 2020 Nov 17;64(12):e01897-20. doi: 10.1128/AAC.01897-20. Print 2020 Nov 17. Antimicrob Agents Chemother. 2020. PMID: 32958718 Free PMC article. Clinical Trial.
Continuous flow synthesis.
Yoshida J, Nagaki A, Yamada D. Yoshida J, et al. Drug Discov Today Technol. 2013 Spring;10(1):e53-9. doi: 10.1016/j.ddtec.2012.10.013. Drug Discov Today Technol. 2013. PMID: 24050230 Review.
The therapeutic potential of mitochondrial toxins.
Kawada M, Amemiya M, Yoshida J, Ohishi T. Kawada M, et al. Among authors: yoshida j. J Antibiot (Tokyo). 2021 Oct;74(10):696-705. doi: 10.1038/s41429-021-00436-z. Epub 2021 Jun 23. J Antibiot (Tokyo). 2021. PMID: 34163026 Review.
Flow microreactor synthesis in organo-fluorine chemistry.
Amii H, Nagaki A, Yoshida J. Amii H, et al. Among authors: yoshida j. Beilstein J Org Chem. 2013 Dec 5;9:2793-802. doi: 10.3762/bjoc.9.314. Beilstein J Org Chem. 2013. PMID: 24367443 Free PMC article. Review.
1,377 results